Vmn1r160 Activators
Vmn1r160 Activators encompass a range of chemical compounds that indirectly augment Vmn1r160's functional activity through specific signaling pathways. For instance, Forskolin, by elevating cAMP levels, activates protein kinase A (PKA), which phosphorylates various substrates potentially influencing Vmn1r160's signaling pathways. Similarly, IBMX and Rolipram, both phosphodiesterase inhibitors, increase cAMP levels, thus leading to PKA activation. This, in turn, may modulate the functional activity of Vmn1r160 indirectly. Sildenafil and Zaprinast, which enhance cGMP levels through phosphodiesterase inhibition, activate PKG, a kinase that could interact with Vmn1r160-related pathways, indirectly enhancing its activity. Additionally, Cilostamide and Milrinone, phosphodiesterase 3 inhibitors, elevate cAMP levels, potentially affecting Vmn1r160 activity through PKA activation. These compounds collectively demonstrate how manipulating cAMP and cGMP levels can indirectly influence Vmn1r160's function.
Furthermore, adrenergic agonists like Isoproterenol, Dobutamine, Norepinephrine, and Epinephrine, through their action on adrenergic receptors, increase cAMP levels and thus PKA activation, which can indirectly modulate Vmn1r160's pathways. Glucagon, by binding to its receptor and elevating cAMP levels, also leads to PKA activation. This cascade of events, starting from receptor activation to downstream kinase activation, exemplifies how the modulation of second messenger systems can play a critical role in influencing the functional activity of Vmn1r160. These activators, by targeting specific signaling pathways and enzymes, collectively contribute to the enhanced activation of Vmn1r160, demonstrating the intricate network of cellular signaling that regulates its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin raises intracellular cAMP levels, triggering protein kinase A (PKA) activation. PKA phosphorylates substrates potentially interacting with Vmn1r160, thereby indirectly enhancing Vmn1r160 activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX inhibits phosphodiesterases, leading to increased cAMP and cGMP levels in cells. This elevation can activate PKA and PKG, which may interact with pathways involving Vmn1r160, indirectly enhancing its activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
As a selective inhibitor of phosphodiesterase 4, Rolipram increases cAMP levels, which can activate PKA. PKA potentially modulates pathways linked to Vmn1r160, indirectly increasing its functional activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast inhibits phosphodiesterases 5 and 6, increasing cGMP levels and potentially activating PKG. PKG activation may indirectly enhance Vmn1r160's activity by modulating related signaling pathways. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Cilostamide, a phosphodiesterase 3 inhibitor, elevates cAMP levels, potentially activating PKA. This activation could influence pathways involving Vmn1r160, indirectly enhancing its function. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
As another phosphodiesterase 3 inhibitor, Milrinone raises intracellular cAMP levels. The subsequent activation of PKA may indirectly enhance Vmn1r160 activity by influencing associated signaling pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, elevates cAMP levels, leading to PKA activation. This activation could enhance Vmn1r160 activity by modulating related signaling pathways. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine, acting as a beta-1 adrenergic agonist, increases cAMP levels, potentially activating PKA. PKA may then modulate pathways associated with Vmn1r160, indirectly enhancing its activity. | ||||||
L-Noradrenaline | 51-41-2 | sc-357366 sc-357366A | 1 g 5 g | $320.00 $475.00 | 3 | |
Norepinephrine, through its action on alpha and beta-adrenergic receptors, can increase cAMP levels, leading to PKA activation. This may indirectly enhance Vmn1r160's function by modulating related pathways. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $40.00 $102.00 $197.00 $1739.00 $16325.00 | ||
Epinephrine, engaging with alpha and beta-adrenergic receptors, elevates cAMP levels. The resulting PKA activation could indirectly increase Vmn1r160 activity by influencing associated signaling pathways. | ||||||